CHCWM – Cancer & Hematology Centers of West Michigan

C4391001 ( Pfizer)

Description:  A Phase 1/1B Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PF-07220060 as a Single Agent and As Part of Combination Therapy In Participants With Advanced Solid Tumors.

Mechanism of Action:  CDK4 inhibitor

Target Patient Population:   Metastatic Breast Cancer, NSCLC (adeno), Prostate cancer, Colorectal cancer, Liposarcoma and tumor types with CDK4 or CCND1 amplification; in combination with letrozole/fulvestrant for HR+ HER2- breast cancer

Study Design:  Drug is given orally twice daily